Feasibility Study of Anti-VEGF Instead of Intraoperative PRP in Proliferative Diabetic Retinopathy

Wenzhou Medical University0 sites220 target enrollmentSeptember 1, 2018

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Anti-VEGF
Sponsor: Wenzhou Medical University
Enrollment: 220
Primary Endpoint: Mean change from baseline in best-corrected visual acuity (BCVA)
Last Updated: 7 years ago

To evaluate the efficacy and safety of vitreoretinal surgery combined with anti-VEGF therapy in the replacement of intraoperative PRP in PDR therapy.

Registry

clinicaltrials.gov

Start Date

September 1, 2018

End Date

December 1, 2022

Last Updated

7 years ago

Study Type

Interventional

Study Design

Parallel

Sex

All

Sponsor

Responsible Party

Principal Investigator

Xiangtian Zhou

professor

Wenzhou Medical University

•Age≥18 years old;
•type 1 or type 2 diabetes.
•proliferative diabetic retinopathy with vitreous hemorrhage, and conservative treatment of vitreous hemorrhage without obvious absorption for 1 month requires vitreoretinal surgery;
•The postoperative refractive medium is clear and the pupil is large enough to obtain sufficient clear fundus

•Previously received panretinal photocoagulation or unfinished panretinal photocoagulation;
•Pulling retinal detachment involving the macula or the presence of extensive fiber proliferation requires silicone oil filling;
•anterior chamber neovascularization or neovascular glaucoma;
•other vascular diseases such as retinal vein occlusion, arterial occlusion, etc;
•received intraocular anti-VEGF therapy or triamcinolone acetonide treatment which are still in the treatment period.